BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 30885150)

  • 1. The small molecule Bcl-2/Mcl-1 inhibitor TW-37 shows single-agent cytotoxicity in neuroblastoma cell lines.
    Klenke S; Akdeli N; Stelmach P; Heukamp L; Schulte JH; Bachmann HS
    BMC Cancer; 2019 Mar; 19(1):243. PubMed ID: 30885150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule inhibitor TW-37 is tolerable and synergistic with chemotherapy in nasopharyngeal carcinoma.
    Lu Y; Huang H; Yang H; Chen D; Wu S; Jiang Z; Wang R
    Cell Cycle; 2017 Jul; 16(14):1376-1383. PubMed ID: 28696828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.
    Bate-Eya LT; den Hartog IJ; van der Ploeg I; Schild L; Koster J; Santo EE; Westerhout EM; Versteeg R; Caron HN; Molenaar JJ; Dolman ME
    Oncotarget; 2016 May; 7(19):27946-58. PubMed ID: 27056887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
    Mohammad RM; Goustin AS; Aboukameel A; Chen B; Banerjee S; Wang G; Nikolovska-Coleska Z; Wang S; Al-Katib A
    Clin Cancer Res; 2007 Apr; 13(7):2226-35. PubMed ID: 17404107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status.
    Al-Katib AM; Sun Y; Goustin AS; Azmi AS; Chen B; Aboukameel A; Mohammad RM
    J Hematol Oncol; 2009 Feb; 2():8. PubMed ID: 19220884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A direct comparison of selective BH3-mimetics reveals BCL-X
    Bierbrauer A; Jacob M; Vogler M; Fulda S
    Br J Cancer; 2020 May; 122(10):1544-1551. PubMed ID: 32203216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
    Tanos R; Karmali D; Nalluri S; Goldsmith KC
    BMC Cancer; 2016 Feb; 16():97. PubMed ID: 26874859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-molecule inhibitor of Bcl-2 (TW-37) suppresses growth and enhances cisplatin-induced apoptosis in ovarian cancer cells.
    Wang H; Zhang Z; Wei X; Dai R
    J Ovarian Res; 2015 Feb; 8():3. PubMed ID: 25823945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1.
    Wu H; Schiff DS; Lin Y; Neboori HJ; Goyal S; Feng Z; Haffty BG
    Radiat Res; 2014 Dec; 182(6):618-25. PubMed ID: 25409124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation and critical assessment of putative MCL-1 inhibitors.
    Varadarajan S; Vogler M; Butterworth M; Dinsdale D; Walensky LD; Cohen GM
    Cell Death Differ; 2013 Nov; 20(11):1475-84. PubMed ID: 23832116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification.
    Roy Choudhury S; Karmakar S; Banik NL; Ray SK
    Invest New Drugs; 2010 Dec; 28(6):812-24. PubMed ID: 19777160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis.
    Ashimori N; Zeitlin BD; Zhang Z; Warner K; Turkienicz IM; Spalding AC; Teknos TN; Wang S; Nör JE
    Mol Cancer Ther; 2009 Apr; 8(4):893-903. PubMed ID: 19372562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species.
    Verhaegen M; Bauer JA; Martín de la Vega C; Wang G; Wolter KG; Brenner JC; Nikolovska-Coleska Z; Bengtson A; Nair R; Elder JT; Van Brocklin M; Carey TE; Bradford CR; Wang S; Soengas MS
    Cancer Res; 2006 Dec; 66(23):11348-59. PubMed ID: 17145881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The preclinical analysis of TW-37 as a potential anti-colorectal cancer cell agent.
    Lei S; Ding Y; Fu Y; Wu S; Xie X; Wang C; Liang H
    PLoS One; 2017; 12(10):e0184501. PubMed ID: 29065135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway.
    Wang Z; Azmi AS; Ahmad A; Banerjee S; Wang S; Sarkar FH; Mohammad RM
    Cancer Res; 2009 Apr; 69(7):2757-65. PubMed ID: 19318573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of novel pyrrolomycin MP1 in MYCN amplified chemoresistant neuroblastoma cell lines alone and combined with temsirolimus.
    McGuire TR; Coulter DW; Bai D; Sughroue JA; Li J; Yang Z; Qiao Z; Liu Y; Murry DJ; Chhonker YS; McIntyre EM; Alexander G; Sharp JG; Li R
    BMC Cancer; 2019 Aug; 19(1):837. PubMed ID: 31455317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of MYCN protein by CX-5461 leads to neuroblastoma tumor growth suppression.
    Taylor JS; Zeki J; Ornell K; Coburn J; Shimada H; Ikegaki N; Chiu B
    J Pediatr Surg; 2019 Jun; 54(6):1192-1197. PubMed ID: 30879743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venetoclax-based Rational Combinations are Effective in Models of
    Dalton KM; Krytska K; Lochmann TL; Sano R; Casey C; D'Aulerio A; Khan QA; Crowther GS; Coon C; Cai J; Jacob S; Kurupi R; Hu B; Dozmorov M; Greninger P; Souers AJ; Benes CH; Mossé YP; Faber AC
    Mol Cancer Ther; 2021 Aug; 20(8):1400-1411. PubMed ID: 34088831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer.
    Wang Z; Song W; Aboukameel A; Mohammad M; Wang G; Banerjee S; Kong D; Wang S; Sarkar FH; Mohammad RM
    Int J Cancer; 2008 Aug; 123(4):958-66. PubMed ID: 18528859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins.
    Wang G; Nikolovska-Coleska Z; Yang CY; Wang R; Tang G; Guo J; Shangary S; Qiu S; Gao W; Yang D; Meagher J; Stuckey J; Krajewski K; Jiang S; Roller PP; Abaan HO; Tomita Y; Wang S
    J Med Chem; 2006 Oct; 49(21):6139-42. PubMed ID: 17034116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.